Key result
Low-dose subcutaneous heparin prevented deep vein thrombosis compared to control in surgical patients, though 80% of treated patients experienced treatment-related complications.
Why the study?
Does low-dose subcutaneous heparin prevent deep vein thrombosis in patients undergoing surgical operations?
Does low-dose subcutaneous heparin prevent deep vein thrombosis in patients undergoing surgical operations?
Low-dose subcutaneous heparin prevented deep vein thrombosis in surgical patients but was associated with a high rate of treatment-related complications.
Answers are grounded in this paper and cite their sources.
High complication rate cautions against routine use despite DVT prevention; leaves open safer prophylaxis strategies in modern randomized trials.
The prophylactic effect of lowaosc heparm (Calciparine)administered subcutaneously to a series of 50 patients undergoing a variety of surgical operations was studied. Four out of a control group of 25 patients (16%)developed deep vem thrombosis, while no patient in the treated group developed it. There was no evidence of pulmonary embolus in either group of patients. Twenty out of the 25 patients who received Calciparine had a complication related to the treatment, in five this was severe enough to cause the Calciparine administration to be stopped.
No takes yet. Share an insight, caveat, or question.
Propsting et al. (1974) studied Deep vein thrombosis (n=50). Low-dose heparin (Calciparine) vs. Control was evaluated on Deep vein thrombosis. Low-dose subcutaneous heparin prevented deep vein thrombosis compared to control in surgical patients, though 80% of treated patients experienced treatment-related complications.
Synapse has enriched 10 related papers. Consider them for comparative context: